China3D printingNet October 19th, the bio-manufacturing competition is underway. Scientists all over the world are competing, and the rise of biotech commercial players has diversified the field and quickly caught up with the high expectations of scientists, healthcare providers, and pharmaceutical companies eager to use this research for clinical treatment. But this is not an easy transition, and even if bioprinting advances the field, it is not as close to patients as everyone hoped. A new company is now delivering a different message, a possibility and hope that can pave the way for the future of healthcare.
The newly launched mimiX biotherapy is developing next-generation biomanufacturing solutions to provide immediate medical tissue engineering for regeneration, personalization and precision medicine. The company was founded by Marc Thurner, who left his previous creation regenHU this year and is now opening a new chapter in his life. The company will use a new biological processing technology called acoustic-induced morphogenesis. commercialize. Senna-now the CEO of mimiX Biotherapeutics-has a new starting point, and he hopes to commercialize it next summer.
“Can we accelerate the biomanufacturing revolution in the healthcare industry?” Senna asked in June.
This is a big question, and he believes he has found the answer.
“After leaving regenHU, I started to travel to the countryside with my family. But I quickly transferred from camping experience to a new high-tech enterprise. Tiziano Serra (the inventor of 3D-SIM technology) came to me and claimed that he was in the bio The manufacturing field has an interesting technology. After spending a week studying the amazing scientific results and data he has achieved in the past six years, I think this is an opportunity I can’t miss,” Senna revealed. He said: “At the time, I realized that most bioprinting companies have technologies based on conventional extrusion systems, which are important tools for scientific research, but they may never be translated into a clinical environment.”
On the contrary, mimiX biotherapeutic technology has been proven through scientific evidence that it provides tissue engineering strategies to overcome today’s obstacles, such as creating dense cell networks suitable for microvascular formation.
The use of conventional dispensing systems for bioprinting is beneficial to science, but due to several key obstacles including scalability, affordability, manufacturing, etc., and because they involve complex and labor-intensive processes, they are too complicated for clinical use .
He also claimed that currently available cell therapies are expensive and time-consuming because the patient’s own biopsy is sent to the laboratory where it is used3D printing(Or other more conventional methods) Isolate and expand cells to create artificial tissues so that they can-weeks later
0 Comments for “Scientists develop 3D-SIM technology to use doctors for bio 3D printing in operating rooms”